HiFiBiO Therapeutics Doses First Patient with HFB200301 in Combination with Tislelizumab for Advanced Solid Tumors

HiFiBiO Therapeutics has announced that the first patient has been dosed with HFB200301, a monoclonal antibody in combination with tislelizumab for the treatment of advanced solid tumor indications preselected by HiFiBiO’s proprietary Drug Intelligence Science (DIS®) platform. The Phase 1a/b study will investigate the safety and tolerability of this combination therapy, and data from the trial w..